Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Contusugene ladenovec (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Liver metastases; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors MultiVir
- 30 May 2020 Status changed from recruiting to discontinued.
- 07 Aug 2018 Planned End Date changed from 20 Aug 2020 to 20 Sep 2020.
- 07 Aug 2018 Planned initiation date changed from 20 Aug 2018 to 20 Sep 2018.